Clinical Trial Update: Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of TAK-935 as an adjunctive therapy for developmental and/or epileptic encephalopathies has been completed with results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental and Epileptic Encephalopathy

Drugs mentioned

• TAK-935

Snippet

Sponsor: Takeda | Conditions: Developmental and/or Epileptic Encephalopathies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-10